StockNews.AI

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

StockNews.AI • 2 days

BWAYPREM
High Materiality8/10

Information

New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients ...

Original source

AI Summary

BrainsWay's SWIFT protocol receives expanded coverage from Premera Blue Cross Blue Shield for patients aged 15 and older with moderate to severe major depressive disorder. This policy enables quicker recovery times and highlights BrainsWay's leadership in noninvasive neurostimulation technology.

Trading Thesis

Investors should consider BWAY bullish due to expanded insurance coverage enhancing revenue potential.

Market-Moving

  • Expanded insurance coverage can significantly increase patient accessibility for BWAY's treatments.
  • Potential for heightened demand following Premera's decision to cover the SWIFT protocol.
  • SWIFT protocol's innovative approach may attract further payer partnerships.
  • Clinical efficacy may drive broader market acceptance and sales growth.
  • Improvements in mental health treatments are garnering increasing attention from investors.

Key Facts

  • Premera serves over 2.8 million covered lives in Alaska and Washington.
  • BrainsWay offers the only FDA-cleared Deep TMS protocols for multiple conditions.
  • SWIFT treatment has a total of 38 sessions, accelerated compared to traditional methods.
  • The company was founded in 2003 and operates in the U.S. and Israel.

Companies Mentioned

  • Premera Blue Cross Blue Shield (N/A): Its coverage expansion significantly benefits BrainsWay, increasing market penetration.
  • BrainsWay (BWAY): BWAY's stock may rise in response to strengthened market position.

Corporate Developments

The announcement highlights a significant development in the mental health treatment sector, emphasizing growing insurance acceptance of innovative therapies. This trend points towards potential changes in investor interest in neurostimulation technologies, making it a critical area for stakeholder education and marketing efforts.

FAQ

Why Bullish?

The expansion of reimbursement suggests growing recognition and adoption of BWAY’s technology, similar to historical examples where institutional support led to stock appreciation in healthcare tech companies.

How important is it?

The article discusses direct advancements in BrainsWay’s treatment coverage affecting market dynamics, thereby having a high likelihood of influencing stock performance.

Why Long Term?

As insurance coverage solidifies, it will likely lead to sustained revenue growth, similar to other healthcare companies facing regulatory recognition.

Related Companies

BWAYPREM

BrainsWay Secures First Coverage Policy for Accelerated Deep TMS™

Date: January 07, 2026 | Source: GlobeNewsWire

New Policy Expands Access for Depression Treatment

BURLINGTON, Mass. and JERUSALEM – BrainsWay Ltd. (NASDAQ & TASE: BWAY), a leader in innovative noninvasive brain stimulation technologies, announced on January 7, 2026, the adoption of a new final medical policy by Premera Blue Cross Blue Shield®. This policy extends coverage to patients aged 15 and older with moderate to severe major depressive disorder (MDD) utilizing BrainsWay’s accelerated SWIFT™ (Short-course with Intrinsic Field Targeting) Deep TMS™ protocol.

“We are elated at Premera’s decision to formally adopt a policy covering our SWIFT depression protocol, which marks a first among payers,” said Hadar Levy, Chief Executive Officer of BrainsWay. The SWIFT protocol is designed to provide faster treatment compared to the standard Deep TMS protocol, allowing patients to experience significant improvements more quickly.

Details of the Accelerated SWIFT Protocol

The SWIFT depression protocol involves an acute treatment phase consisting of five ten-minute sessions per day for six days, followed by two sessions per day once a week for four weeks, totaling 38 sessions. Notably, this approach eliminates the need for expensive functional MRI or neuronavigational equipment.

Colleen Hanlon, PhD, Vice President of Medical Affairs at BrainsWay, commented, “Our clinical trials and real-world data indicate that the SWIFT accelerated depression protocol yields comparable response and remission rates to our standard Deep TMS protocol. We are dedicated to educating stakeholders on the robust data supporting increased coverage for this innovative treatment.”

About BrainsWay and Its Leadership in Neurostimulation

BrainsWay stands at the forefront of noninvasive neurostimulation therapies for mental health disorders. With its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, the company aims to enhance health outcomes and transform lives. BrainsWay is currently the only TMS provider with three FDA-cleared indications validated by extensive clinical research.

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Smoking Addiction

Founded in 2003 and operating in both the United States and Israel, BWAY is focused on raising awareness and expanding access to Deep TMS technologies. The company is actively conducting additional clinical trials to explore its applications in various psychiatric, neurological, and addiction disorders.

Looking Ahead

This announcement comes amid ongoing efforts by BrainsWay to expand coverage and improve treatment options for patients battling depression. As the implications of this new policy unfold, BWAY remains committed to advancing neurostimulation therapies to enhance patient outcomes.

Contact Information

For further inquiries, please reach out to:

Ido Marom, Chief Financial Officer, BWAY
Email: Ido.Marom@BrainsWay.com

Investors Contact:
Brian Ritchie, LifeSci Advisors
Email: britchie@lifesciadvisors.com

Related News